NCT07180862View on ClinicalTrials.gov

A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

November 30, 2027

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

BAT3306

One vial of 4 mL of concentrate contains 100 mg of BAT3306

DRUG

US-Keytruda®

One vial of 4 mL of concentrate contains 100 mg of pembrolizumab

Trial Locations (1)

Unknown

Union Hospital Tongji Medical College Huazhong University of Science & Technology, Wuhan

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY